Novel inhaled formulation of dihydroergotamine effective for a broad spectrum of migraine:
MAP0004, a novel orally inhaled formulation of dihydroergotamine currently under development, may be effective in treating a broad spectrum of migraine, according to 2 phase 3 studies presented here September 12 at the 14th Congress of the International Headache Society & the 51st Annual Scientific Meeting of the American Headache Society.
An epilepsy drug which may also be used to control migraine headaches can cause birth defects in babies born to women taking the drug.